Welcome to the BioLogicTube jeo@biologicmedia.dk https://biologictube.dk/app/facebook en-us Visualplatform http://blogs.law.harvard.edu/tech/rss Welcome to the BioLogicTube episodic no https://biologictube.dk/app/facebook/files/rv0.0/sitelogo.gif https://biologictube.dk/app/facebook http://biologictube.dk/photo/9570914/lifandis-unlocking-the-secrets-of <p><p>Lifandis links the industry to a wealth of biological samples from the HUNT studies. It is the&nbsp;entry point to a unique set of biological samples and extensive clinical and longitudinal data based on the Norwegian population. By connecting industry to high quality biosamples, a comprehensive network of national health registries, and depth information about health and disease we offer unparalleled access to this population.</p><p>Lifandis advances disease understanding and leads to better healthcare products.</p><p>Lifandis is owned by the Norwegian University of Science and Technology, the Central Norway Health Authority and the Nord-Trøndelag County.</p><p>The company changed its name from Hunt Biosciences AS to Lifandis AS as of April 1, 2014.</p><p>For more info, please check www.lifandis.com</p></p><p><a href="http://biologictube.dk/photo/9570914/lifandis-unlocking-the-secrets-of"><img src="http://biologictube.dk/7718124/9570914/dafd83fdea3c02e98d41668653339e59/standard/download-1-thumbnail.jpg" width="600" height="338"/></a></p> http://biologictube.dk/photo/9570914 Wed, 09 Apr 2014 14:29:18 GMT Lifandis - Unlocking the secrets of disease Lifandis links the industry to a wealth of biological samples from the HUNT studies. It is theentry point to a unique set of biological samples and extensive clinical and longitudinal data based on the Norwegian population. By connecting industry to high quality biosamples, a comprehensive network of national health registries, and depth information about health and disease we offer unparalleled access to this population.Lifandis advances disease understanding and leads to better healthcare products.Lifandis is owned by the Norwegian University of Science and Technology, the Central Norway Health Authority and the Nord-Trøndelag County.The company changed its name from Hunt Biosciences AS to Lifandis AS as of April 1, 2014.For more info, please check www.lifandis.com Lifandis links the industry to a wealth of biological samples from the HUNT studies. It is theentry point to a unique set of biological samples and extensive clinical and longitudinal data based on the Norwegian population. By connecting industry... Welcome to the BioLogicTube 03:40 <p><p>Lifandis links the industry to a wealth of biological samples from the HUNT studies. It is the&nbsp;entry point to a unique set of biological samples and extensive clinical and longitudinal data based on the Norwegian population. By connecting industry to high quality biosamples, a comprehensive network of national health registries, and depth information about health and disease we offer unparalleled access to this population.</p><p>Lifandis advances disease understanding and leads to better healthcare products.</p><p>Lifandis is owned by the Norwegian University of Science and Technology, the Central Norway Health Authority and the Nord-Trøndelag County.</p><p>The company changed its name from Hunt Biosciences AS to Lifandis AS as of April 1, 2014.</p><p>For more info, please check www.lifandis.com</p></p><p><a href="http://biologictube.dk/photo/9570914/lifandis-unlocking-the-secrets-of"><img src="http://biologictube.dk/7718124/9570914/dafd83fdea3c02e98d41668653339e59/standard/download-1-thumbnail.jpg" width="600" height="338"/></a></p> biobank biotech data databank diagnosis diagnostics disease followup genetics health id norway prognosis http://biologictube.dk/photo/7529380/the-value-of-spin-outs-by <p>What is the societal value of public biotech Spin-outs? Where is the link to industry and how should central administration support it? Martin Bonde explains what it takes to make it and what value it provides.<br></p><p><a href="http://biologictube.dk/photo/7529380/the-value-of-spin-outs-by"><img src="http://biologictube.dk/7522146/7529380/2727abd69eb8fe7c97de4a12e6932098/standard/download-1-thumbnail.jpg" width="600" height="338"/></a></p> http://biologictube.dk/photo/7529380 Tue, 29 Jan 2013 20:18:54 GMT The value of Spin-outs by Martin Bonde, Chairman Dansk Biotek and Copenhagen... What is the societal value of public biotech Spin-outs? Where is the link to industry and how should central administration support it? Martin Bonde explains what it takes to make it and what value it provides. What is the societal value of public biotech Spin-outs? Where is the link to industry and how should central administration support it? Martin Bonde explains what it takes to make it and what value it provides. Welcome to the BioLogicTube 31:45 <p>What is the societal value of public biotech Spin-outs? Where is the link to industry and how should central administration support it? Martin Bonde explains what it takes to make it and what value it provides.<br></p><p><a href="http://biologictube.dk/photo/7529380/the-value-of-spin-outs-by"><img src="http://biologictube.dk/7522146/7529380/2727abd69eb8fe7c97de4a12e6932098/standard/download-1-thumbnail.jpg" width="600" height="338"/></a></p> IPR biotech biotek capital creation danish dansk job region research talents technology transfer http://biologictube.dk/photo/7530745/jeff-skinner-director-london <p><p><b>Jeff Skinner</b>&nbsp;is the Executive Director of the Deloitte Institute of Innovation and Entrepreneurship at London Business School. He also directs a variety of MBA entrepreneurship electives and co-curricula student activities at the School. He is visiting lecturer on Technology Transfer at University College London and at the Graduate School of Economics in Barcelona. Prior to this, as Commercial Director at University College London, he conceived, built and ran UCL’s Technology Transfer division - including the creation of two early-stage seed funds and separate units managing consultancy, collaborative research and new venture creation. Working alongside research students and academics he has co-founded over thirty technology-based spin-outs that have, in aggregate, raised over £30 million first round finance and returned over £20 million to UCL.</p><p>He is past President of and remains closely involved with the leading UK &amp; European Tech Transfer Associations (PraxisUnico &amp; ASTP). He teaches and consults widely throughout Europe in the field of technology commercialisation. He Chairs the Professional Recognition panel for the worldwide ‘Alliance of Technology Transfer Professionals’.</p><p>Before joining UCL he was Technical Marketing Manager at Hoechst Celanese Corporation in New Jersey and prior to that, Photonics Research Manager at General Electric. His first degree was in physics. He holds a PhD in thin-film photonics from University College London and an MBA from London Business School.</p></p><p><a href="http://biologictube.dk/photo/7530745/jeff-skinner-director-london"><img src="http://biologictube.dk/7522146/7530745/ef0b3f0ece6fe971f78680e32924068b/standard/download-1-thumbnail.jpg" width="600" height="338"/></a></p> http://biologictube.dk/photo/7530745 Mon, 31 Dec 2012 14:43:27 GMT Jeff Skinner, Director, London Business School, talks on his experience from... Jeff Skinneris the Executive Director of the Deloitte Institute of Innovation and Entrepreneurship at London Business School. He also directs a variety of MBA entrepreneurship electives and co-curricula student activities at the School. He is visiting lecturer on Technology Transfer at University College London and at the Graduate School of Economics in Barcelona. Prior to this, as Commercial Director at University College London, he conceived, built and ran UCL’s Technology Transfer division - including the creation of two early-stage seed funds and separate units managing consultancy, collaborative research and new venture creation. Working alongside research students and academics he has co-founded over thirty technology-based spin-outs that have, in aggregate, raised over £30 million first round finance and returned over £20 million to UCL.He is past President of and remains closely involved with the leading UK European Tech Transfer Associations (PraxisUnico ASTP). He teaches and consults widely throughout Europe in the field of technology commercialisation. He Chairs the Professional Recognition panel for the worldwide ‘Alliance of Technology Transfer Professionals’.Before joining UCL he was Technical Marketing Manager at Hoechst Celanese Corporation in New Jersey and prior to that, Photonics Research Manager at General Electric. His first degree was in physics. He holds a PhD in thin-film photonics from University College London and an MBA from London Business School. Jeff Skinneris the Executive Director of the Deloitte Institute of Innovation and Entrepreneurship at London Business School. He also directs a variety of MBA entrepreneurship electives and co-curricula student activities at the School. He is... Welcome to the BioLogicTube 01:06:00 <p><p><b>Jeff Skinner</b>&nbsp;is the Executive Director of the Deloitte Institute of Innovation and Entrepreneurship at London Business School. He also directs a variety of MBA entrepreneurship electives and co-curricula student activities at the School. He is visiting lecturer on Technology Transfer at University College London and at the Graduate School of Economics in Barcelona. Prior to this, as Commercial Director at University College London, he conceived, built and ran UCL’s Technology Transfer division - including the creation of two early-stage seed funds and separate units managing consultancy, collaborative research and new venture creation. Working alongside research students and academics he has co-founded over thirty technology-based spin-outs that have, in aggregate, raised over £30 million first round finance and returned over £20 million to UCL.</p><p>He is past President of and remains closely involved with the leading UK &amp; European Tech Transfer Associations (PraxisUnico &amp; ASTP). He teaches and consults widely throughout Europe in the field of technology commercialisation. He Chairs the Professional Recognition panel for the worldwide ‘Alliance of Technology Transfer Professionals’.</p><p>Before joining UCL he was Technical Marketing Manager at Hoechst Celanese Corporation in New Jersey and prior to that, Photonics Research Manager at General Electric. His first degree was in physics. He holds a PhD in thin-film photonics from University College London and an MBA from London Business School.</p></p><p><a href="http://biologictube.dk/photo/7530745/jeff-skinner-director-london"><img src="http://biologictube.dk/7522146/7530745/ef0b3f0ece6fe971f78680e32924068b/standard/download-1-thumbnail.jpg" width="600" height="338"/></a></p> Balling Copenhagen Gert IPR Spin biotech building chain innovation outs patents value http://biologictube.dk/photo/7526773/there-is-a-need-to-strengthen <p><p>Thomas Christiansen explains the&nbsp;Government perspective on bridging public research and industry</p><div><br></div></p><p><a href="http://biologictube.dk/photo/7526773/there-is-a-need-to-strengthen"><img src="http://biologictube.dk/7522146/7526773/792a0844db51cc49da9088e78be2bdfd/standard/download-1-thumbnail.jpg" width="600" height="338"/></a></p> http://biologictube.dk/photo/7526773 Sun, 30 Dec 2012 09:24:04 GMT There is a need to strengthen and stimulate the cooperation between... Thomas Christiansen explains theGovernment perspective on bridging public research and industry Thomas Christiansen explains theGovernment perspective on bridging public research and industry Welcome to the BioLogicTube 43:28 <p><p>Thomas Christiansen explains the&nbsp;Government perspective on bridging public research and industry</p><div><br></div></p><p><a href="http://biologictube.dk/photo/7526773/there-is-a-need-to-strengthen"><img src="http://biologictube.dk/7522146/7526773/792a0844db51cc49da9088e78be2bdfd/standard/download-1-thumbnail.jpg" width="600" height="338"/></a></p> biotech funding future jobs key politics sector technology transfer view http://biologictube.dk/photo/7525099/henric-rhedin-talks-on-the <p><p>Sweden’s so called innovation system; a spin out creation system. <br></p><p>Henric Rhedin. Director of Sales &amp; Marketing, Commercial Research &amp; Development. Chalmers Industriteknik, Gothenburg In Sweden there has been a focus on creating spin outs as commercialization strategy. What are the advan-tages/ disadvantages with a “spin out creation system” compared to more regular “innovation systems</p><p>Chalmers Industrial Technologies (CIT) is Sweden ́s oldest technology transfer organization and dates back to 1984. Henric works since nine years back for the largest unit at CIT, 35 people out of a total of 75 people employed by CIT. The unit, Commercial R&amp;D, provides expertise in all kinds of areas of technology including technology management and related services.</p> <p>Henric is board member for several start up companies as well as organizations. In addition to this Henric is active in innovation system networks on the national as well as on the international level including Association of Science and Technology Transfer Professional (ASTP), HEP TTN a CERN centered network for technology transfer activities for high energy physics, Swedish Network for Innovation and Tech Transfer Support (SNITTS) and Nordic Tech Transfer Network Health (NORTTH). Henric has also worked in the Swedish defense industry and has a PhD in Theoretical High Energy Physics.</p><br></p><p><a href="http://biologictube.dk/photo/7525099/henric-rhedin-talks-on-the"><img src="http://biologictube.dk/7522146/7525099/d61f3cb3a2f6de363b28e3766689578a/standard/download-1-thumbnail.jpg" width="600" height="338"/></a></p> http://biologictube.dk/photo/7525099 Sat, 29 Dec 2012 16:06:01 GMT Henric Rhedin talks on the swedish innovator system Sweden’s so called innovation system; a spin out creation system. Henric Rhedin. Director of Sales Marketing, Commercial Research Development. Chalmers Industriteknik, Gothenburg In Sweden there has been a focus on creating spin outs as commercialization strategy. What are the advan-tages/ disadvantages with a “spin out creation system” compared to more regular “innovation systemsChalmers Industrial Technologies (CIT) is Sweden ́s oldest technology transfer organization and dates back to 1984. Henric works since nine years back for the largest unit at CIT, 35 people out of a total of 75 people employed by CIT. The unit, Commercial RD, provides expertise in all kinds of areas of technology including technology management and related services. Henric is board member for several start up companies as well as organizations. In addition to this Henric is active in innovation system networks on the national as well as on the international level including Association of Science and Technology Transfer Professional (ASTP), HEP TTN a CERN centered network for technology transfer activities for high energy physics, Swedish Network for Innovation and Tech Transfer Support (SNITTS) and Nordic Tech Transfer Network Health (NORTTH). Henric has also worked in the Swedish defense industry and has a PhD in Theoretical High Energy Physics. Sweden’s so called innovation system; a spin out creation system. Henric Rhedin. Director of Sales Marketing, Commercial Research Development. Chalmers Industriteknik, Gothenburg In Sweden there has been a focus on creating spin outs as... Welcome to the BioLogicTube 33:15 <p><p>Sweden’s so called innovation system; a spin out creation system. <br></p><p>Henric Rhedin. Director of Sales &amp; Marketing, Commercial Research &amp; Development. Chalmers Industriteknik, Gothenburg In Sweden there has been a focus on creating spin outs as commercialization strategy. What are the advan-tages/ disadvantages with a “spin out creation system” compared to more regular “innovation systems</p><p>Chalmers Industrial Technologies (CIT) is Sweden ́s oldest technology transfer organization and dates back to 1984. Henric works since nine years back for the largest unit at CIT, 35 people out of a total of 75 people employed by CIT. The unit, Commercial R&amp;D, provides expertise in all kinds of areas of technology including technology management and related services.</p> <p>Henric is board member for several start up companies as well as organizations. In addition to this Henric is active in innovation system networks on the national as well as on the international level including Association of Science and Technology Transfer Professional (ASTP), HEP TTN a CERN centered network for technology transfer activities for high energy physics, Swedish Network for Innovation and Tech Transfer Support (SNITTS) and Nordic Tech Transfer Network Health (NORTTH). Henric has also worked in the Swedish defense industry and has a PhD in Theoretical High Energy Physics.</p><br></p><p><a href="http://biologictube.dk/photo/7525099/henric-rhedin-talks-on-the"><img src="http://biologictube.dk/7522146/7525099/d61f3cb3a2f6de363b28e3766689578a/standard/download-1-thumbnail.jpg" width="600" height="338"/></a></p> Experience IPR biotech commercialization patents technology transfer